摘要
目的探讨达比加群酯抗凝治疗高龄女性患者非瓣膜性心房纤颤(房颤)的疗效及安全性。方法选取解放军210医院2014年9月至2015年4月收治的非瓣膜性房颤高龄老年女性(年龄≥80岁)患者9例,给予达比加群酯110 mg,每日2次,观察其抗凝疗效及药物安全性。结果本组9例患者均获得6个月随访。末次随访时,9例患者均无新发脑梗死,无脑出血。药物不良反应方面,2例(22.2%)消化不良,1例(11.1%)上腹痛,患者为空腹服药,纠正为餐后服药后上腹痛缓解;2例(22.2%)皮下瘀斑,1例(11.1%)牙龈出血。无严重出血事件,血红蛋白、血小板、肝功能、肾功能无变化。结论达比加群酯抗凝治疗高龄老年女性患者非瓣膜性房颤安全、有效。
Objective To explore the antithrombotic efficacy and safety of dabigatran etexilate in senile female patients with nonvalvular atrial fibrillation. Methods A retrospective study was performed on the senile female patients（ aged more than 80,n = 9） with nonvalvular atrial fibrillation were received in No. 210 Hospital of PLA from September 2014 to April 2015. Patients were given oral dabigatran etexilate 110 mg once,twice a day. The antithrombotic coagulation efficacy and drug safety were observed. Results This group of 9 patients received 6 months of follow-up. Until the last follow-up,none of the patients got new-onset cerebral infarction or encephalorrhagia. For adverse drug reactions,2 cases（ 22. 2%） with indigestion,1 case（ 11. 1%） with epigastralgia. Patients with abdominal pain was relieved by taking medicine preprandial changed into postprandial. Two cases（ 22. 2%） with subcutaneous ecchymosis,one case（ 11. 1%） with bleeding gums. There were no adverse event of bleeding or significant changes of hemoglobin,platelet,liver function or renal function. Conclusion Dabigatran etexilate is an effective and safe treatment of senile female patients with nonvalvular atrial fibrillation.
出处
《临床军医杂志》
CAS
2016年第9期953-955,共3页
Clinical Journal of Medical Officers
关键词
达比加群酯
心房纤颤
高龄
女性
Dabigatran etexilate
Atrial fibrillation
Senile
Female
